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Argos, a secreted inhibitor of the Drosophila epidermal growth factor receptor, and the only known secreted receptor tyrosine kinase
inhibitor, acts by sequestering the EGFR ligand Spitz. We use computational modeling to show that this biochemically-determined
mechanism of Argos action can explain available genetic data for EGFR/Spitz/Argos interactions in vivo. We find that efficient Spitz
sequestration by Argos is key for explaining the existing data and for providing a robust feedback loop that modulates the Spitz gradient in
embryonic ventral ectoderm patterning. Computational analysis of the EGFR/Spitz/Argos module in the ventral ectoderm shows that Argos
need not be long-ranged to account for genetic data, and can actually have very short range. In our models, Argos with long or short length
scale functions to limit the range and action of secreted Spitz. Thus, the spatial range of Argos does not have to be tightly regulated or may
act at different ranges in distinct developmental contexts.
D 2005 Elsevier Inc. All rights reserved.Keywords: EGFR inhibition; Argos; SpitzIntroduction
Epidermal growth factor receptor (EGFR) is a key
regulator of developing tissues in animals from worms to
humans (Holbro and Hynes, 2004; Moghal and Sternberg,
2003; Shilo, 2003). EGFR activation in vivo is tightly
controlled by ligand availability, receptor-mediated endocy-
tosis, and intracellular inhibitors of EGFR signaling (Harris
et al., 2003; Sweeney and Carraway, 2004). Experiments in
Drosophila have identified a secreted EGFR inhibitor,
Argos, that participates in a negative feedback loop induced
by high levels of EGFR signaling (Casci and Freeman,
1999; Freeman et al., 1992; Schweitzer et al., 1995a; Shilo,
2003). Genetic studies have demonstrated that EGFR0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: stas@princeton.edu (S.Y. Shvartsman).inhibition by Argos is long-ranged in all stages of fruit fly
development (Freeman et al., 1992). Recently, we have
shown biochemically that Argos inhibits EGFR signaling by
sequestering the activating ligand Spitz (Klein et al., 2004).
This direct interaction of Argos and Spitz suggests that the
apparent long-range of EGFR inhibition by Argos may
result not from the long range of the molecule itself, but
from its ability to modulate the gradients of secreted EGFR
agonists such as Spitz (Klein et al., 2004). Sequestration of
EGFR agonists by Argos could result in long-ranged EGFR
inhibition in two different ways. First, by sequestering Spitz
close to the point of its release and thus preventing Spitz
delivery to distant cells, Argos could act as a short-ranged
molecule with long-range effects. Second, Argos could
diffuse to distant cells and inhibit EGFR signaling by
sequestering activating ligands at a distance from the site of
their secretion.
Experimental tests of the ability of Argos to directly
modulate the gradients of locally produced EGFR ligands
require visualizing these gradients in vivo. Currently, these284 (2005) 523 – 535
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of signaling and transcriptional targets of EGFR. To
investigate the spatiotemporal control of EGFR signaling
by Argos, we have developed a computational model of the
EGFR/Spitz/Argos network and used it to study the role of
Argos in cell fate determination in the ventral ectoderm
(Golembo et al., 1996a, b; Kim and Crews, 1993; Lee et al.,
1999; Raz and Shilo, 1993).
In stage 5 of embryonic development, the cellularized
blastoderm contains spatial information that divides the
embryo along its dorsal–ventral axis into distinct domains,
including the presumptive mesodermal, mesectodermal, and
ventral ectodermal domains. The cells in the presumptive
mesoderm, the ventral-most of these domains, invaginate
during gastrulation in stages 6 and 7. This causes the two
presumptive mesectodermal domains, each corresponding to
a single row of cells on either side of the bilaterally symmetric
embryo, to come together to form the ventral midline. After
gastrulation is completed at stage 8, the cell row along theFig. 1. Geometry of the ventral ectoderm. (A) EGFR-mediated cell communicatio
transcription factor sim, which induces the expression of the protease Rhomboid
secreted from the midline cell. Spitz diffuses in the extracellular space to neighb
consequence of EGFR activation, the first 1–2 rows of ventral ectoderm cells exp
headed arrow. The low threshold genes (fasIII) are expressed in 4–5 cell rows (g
ventral-most 1–2 cell rows (as a high threshold gene product) and binds to Spitz
resulting in expansion of the expression domains of the high threshold genes to 3–
Visualization of expression domains of ventral ectoderm markers. (B) Rhomboid
Arrowhead: ventral midline.ventral midline is flanked on either side by the ventral
ectoderm (VE). This cell row expresses the transcription
factor single-minded (sim), which drives expression of the
protease rhomboid (rho) ((Chang et al., 2001, 2003;
Golembo et al., 1996a; Schweitzer et al., 1995b), Fig. 1B).
Rhomboid is responsible for processing the EGFR ligand
Spitz (Spi) into its active form (Lee et al., 2001). Secreted
Spitz (sSpi) is thus produced only in the ventral midline, and
diffuses to induce transcription of EGFR-target genes in the
neighboring VE cells (Fig. 1A). These target genes fall into
two distinct categories: the high-threshold genes, including
pointed (pnt), orthodenticle (otd), and argos (aos), and the
low-threshold genes such as fasciclinIII (fasIII). The high
threshold genes are only expressed in the cells closest to the
source of Spitz, where levels of the activating ligand are
greatest: 1–2 cell rows on either side of the ventral midline
(red arrow in Fig. 1A, (Chang et al., 2001, 2003; Golembo et
al., 1996b; Vivekanand et al., 2004), Figs. 1C, D). Further
from the ligand source, where Spitz levels are reduced, onlyn in the ventral ectoderm. The midline cell is unique in that it expresses the
. Rhomboid in turn processes the EGFR ligand Spitz, enabling Spitz to be
oring ventral ectodermal cells, where it binds to and activates EGFR. As a
ress the high threshold genes (pnt, otd, aos), as denoted by the red double-
reen double-headed arrow). The EGFR inhibitor Argos is secreted from the
in the extracellular space. In the Argos mutant, this inhibition is abolished,
6 cell rows, and the low threshold genes to 6–7 cell rows (see inset). (B–E)
(rho) mRNA. (C) otd mRNA. (D) aos mRNA. (E) FasIII protein (arrows).
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domain extends no more than 4–5 cell rows on either side of
the midline (green arrow in Fig. 1A, (Chang et al., 2001,
2003; Golembo et al., 1996b; Patel et al., 1987; Vivekanand
et al., 2004), Fig. 1E).
Argos appears to have two roles in VE patterning. First,
it limits the lateral extent of Spitz signaling across the
ventral ectoderm. Second, Argos is thought to provide a
negative feedback loop that dampens fluctuations in other
components of this signaling module, and thus contributes
to the robustness of the wild-type expression pattern of
EGFR target genes (Golembo et al., 1996a). The expression
domains of EGFR-target genes are clearly expanded in aos
embryos compared to the wild-type case (Chang et al.,
2001, 2003; Golembo et al., 1996a,b). The high-threshold
domain expands from just 1–2 cell rows on either side of
the midline (in wild type) to 3–6 cells on either side in aos
embryos (Chang et al., 2001, 2003; Golembo et al.,
1996a,b) (red arrow in Fig. 1A, inset). Similarly, the low
threshold domain expands from just 4–5 cell rows in wild
type to 6–7 rows in the aos mutants (Chang et al., 2001;
Golembo et al., 1996a,b) (green arrow in Fig. 1A, inset).
This expansion in the expression domains of EGFR target
genes is accompanied by an increased width of the ventral
epidermis, as measured by the distance between the
precursors of the Keilin’s organs, pairs of ventrolaterally
located sensory organs (Freeman et al., 1992).
We have constrained our quantitative model of the
EGFR/Spitz/Argos system in VE patterning using the
experimentally observed expansions of EGFR-target gene
expression in aos embryos (Golembo et al., 1996b). After
applying these constraints, we find that Argos can exert its
influence on VE patterning by acting at very short range.
Indeed, even when the Argos length scale is set to zero, the
model can fit the experimental data obtained with aos
embryos. Our model also captures the experimentally
observed robustness of the wild type signaling module to
large changes in the doses of Spitz and EGFR (Golembo et
al., 1996a, 1999; Raz and Shilo, 1993). We analyze the
contribution of Argos to this robustness and show that it is
not dependent on Argos being a long-ranged diffusible
molecule: Argos can also achieve its stabilizing effects
through short-range action.
Model of EGFR/Spitz/Argos network in the embryonic
ventral ectoderm
Our model retains the essential interactions in the EGFR/
Spitz/Argos network (Casci and Freeman, 1999; Chang et
al., 2001, 2003; Golembo et al., 1996a,b, 1999; Klein et al.,
2004; Schweitzer et al., 1995b; Shilo, 2003). We model
Spitz diffusion and binding to EGFR, dimerization of Spitz/
EGFR complexes, internalization of dimerized EGF recep-
tors, as well as Argos binding to Spitz (which prevents Spitz
from binding and activating EGFR). All of these inter-
actions have been demonstrated either genetically orbiochemically (Klein et al., 2004; Schweitzer et al.,
1995b). In addition, Argos binds to the surface of
Drosophila cells in culture through an interaction that can
be inhibited by adding excess soluble heparin (Klein et al.,
2004) and may possibly represent association with cell
surface heparan-sulfate proteoglycans (HSPGs). To account
for this, we include a term in our model that describes
binding of Argos to the cell surface and assume that this
represents one route for Argos uptake (and thus removal) in
the ventral ectoderm, as reported for other such interactions
(Colin et al., 1999; Deguchi et al., 2002).
The starting model of EGFR signaling in the ventral
ectoderm has one intracellular, three cell-surface, and three
extracellular variables (see Supplementary Material for the
details of model formulation). The intracellular variable
describes the level of an EGFR-regulated transcription
factor in cell i. This variable lumps the joint effects of
ETS transcriptional activators and repressors, such as
Pointed and Yan, that convert EGFR-mediated MAPK
signaling into the expression of high-threshold genes
(Chang et al., 2001, 2003; Golembo et al., 1996a,b, 1999;
Vivekanand et al., 2004). In the rest of the paper, we refer to
this intracellular variable as ‘‘Pointed’’. The cell surface
variables are the levels of Spitz/EGFR complexes, of cell
surface-bound Argos, and of dimerized receptor. The
extracellular variables represent the concentrations of
diffusing Spitz, Argos, and the Argos/Spitz complex.
The input to the system is modeled as a localized and
constant Spitz generation term that represents the activity of
Rhomboid in the midline cell, which is required for
processing and secretion of active Spitz. In contrast, EGFR
is expressed only in the ventral ectodermal cells, and not in
the midline (Raz and Shilo, 1993; Zak et al., 1990). The
generation rate of the transcription factor that controls the
expression of Argos in cell i is a function of the level of
EGFR activity seen by cell i, which is taken as the total
number of EGFR dimers. Pointed, expressed in response to
high levels of EGFR activation, stimulates Argos secretion
from cell i; this is modeled by a linear generation term in the
equation for Argos. Separate linear processes describe the
endocytosis of dimerized receptor and cell surface bound
Argos, as well as the degradation of the intracellular
transcription factor.
Since secreted Spitz has been identified as a limiting
component in VE patterning (Chang et al., 2001, 2003;
Schweitzer et al., 1995b), we assume that EGFR signaling
in the VE operates in the ligand-limiting regime, meaning
that the number of available receptors is not appreciably
diminished by ligand binding. Thus, the receptor is in
excess and the extent of its activation is controlled by the
availability of secreted Spitz. Our previous analysis of
EGFR activation by Spitz in cultured cells (and consid-
eration of the human EGFR system) indicates that dissoci-
ation of EGFR-bound Spitz is slow compared to the rate of
its internalization (Klein et al., 2004). We therefore assume
that Spitz/EGFR binding is effectively irreversible on the
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biochemical analysis of Argos/Spitz interactions, we assume
that Argos/Spitz binding is irreversible.1 Finally, based on
the fact that ligand-induced EGFR dimerization and
phosphorylation is fast (Klein et al., 2004; Schweitzer et
al., 1995b), we assume that it adjusts instantaneously to the
levels of EGFR-bound Spitz at the cell surface.
With these assumptions, EGFR/Spitz/Argos signaling in
the ventral ectoderm can be described in terms of three
variables: Pi (t), the intracellular level of Pointed in cell i,
and the extracellular concentrations of Argos (A(x,t)) and
Spitz (S(x,t)) (see Supplementary Material for detailed
derivation). For convenience, these variables are rescaled
by their maximal concentrations (given by the balance of
their generation and degradation, see Supplementary Mate-
rial). After rescaling, the variables are denoted by pi (t),
a(x,t), and s(x,t). We choose the cell size as the unit of
length (x).
Equations and parameters
Within the framework of our model, the steady state
pattern of EGFR activation in the ventral ectoderm is
described by the following boundary value problem (see
Supplementary Material for details of model formulation
and analysis):
k2s sxx þ fs xð Þ  fr xð Þs las ¼ 0 ð1Þ
k2aaxx þ fa p; xð Þ  a mas ¼ 0 ð2Þ
Eqs. (1) and (2) describe the spatial profiles of secreted
Spitz and Argos, respectively. The first term in these
equations describes diffusion of secreted ligand (the second
derivative with respective to the spatial coordinate multi-
plied by the corresponding length scale). The center of the
midline cell is chosen as the origin, x = 0. No-flux boundary
conditions are applied for s and a: sx|0,n = 0, ax|0,n = 0,
where the size of the domain corresponds to n cells. The
boldface p refers to the set of Pointed levels, pi, for all cells
i from zero to n.
The source function, fs (x), in Eq. (1) describes the pattern
of Rhomboid expression, and hence the pattern of Spitz
secretion. Rhomboid is expressed only in the midline cell;
assuming symmetry around the midline, we therefore get
fs (x) = 1when x 1/2, and zero otherwise. The function fr (x)
describes the localization of the EGF receptor (Raz and Shilo,
1993; Zak et al., 1990). The source function in the Argos
balance Eq. (2), fa (p,x), describes the spatial pattern of Argos1 In the Supplementary Material, we have also analyzed the limit when
the equilibration of Argos/Spitz binding is infinitely fast. In this regime,
Argos/Spitz binding is always in equilibrium. We have found that while this
limit can describe the experimentally observed cell fate expansions in aos-
embryos, it does not lead to a robust patterning mechanism.release, which is colocalized with the pattern of Pointed
expression; for each cell, fa (p,x) = const = pi. Each of these
functions is illustrated in Fig. 2.
We assume the amount of signal received by cell i is
proportional to the total number of dimerized EGFR
molecules in a cell. This signal, denoted by ri, is propor-
tional to the integral of the free Spitz concentration over that
cell, and thus ri K Xcell i s(x)dx (see the Supplementary
Material for derivation). We model the induction of Pointed
by EGFR as a sharp switch: pi = 1 when ri > hp and zero
otherwise. This means that when the signal received by cell
i (ri) is above the threshold level (hp), pointed will be
expressed in that cell. This reflects the experimentally
observed sharp domains of pnt, otd, and aos expression in
response to the gradient of EGFR activation (Chang et al.,
2001, 2003; Golembo et al., 1996a,b, 1999; Skeath, 1998;
Wessells et al., 1999).
Solution of Eqs. (1) and (2) depends on five dimension-
less parameters (Table 1). Each of these dimensionless
parameters describes the relative importance of competing
physical phenomena. ks, defined as the ratio of the
diffusion length of Spitz to the length of a cell, describes
the balance of Spitz diffusion and degradation. The length
scale of Spitz has been proposed to be 3–4 cell diameters,
and thus we restrict our parameter ks to values between
one and ten (Freeman, 1994). ka is the length scale of
Argos, analogous to ks and has been estimated to be 4–10
cell diameters (Freeman et al., 1992; Golembo et al.,
1996b); we allow ka to vary between zero and ten. The
parameter hp describes the threshold level of EGFR
activity required for pointed expression. We constrain this
parameter using experimental data from wild type embryos
using the protocol described in the next section. The final
two parameters, l and m, are related to Argos/Spitz
binding. l compares the kinetics of removal of free Spitz
due to Argos/Spitz binding to the kinetics of Spitz
degradation due to receptor binding and endocytosis.
Analogous to this, m is the ratio of removal rate of free
Argos due to Argos/Spitz binding to the rate of Argos
degradation associated with cell-surface binding. Based on
surface plasmon resonance data (Klein et al., 2004), we
estimate that l is between 101 and 101, and m, which is
slightly less characterized, is between 102 and 102 (see
the Supplementary Material). These initial estimates are
further refined by fitting experimental data in the aos
mutant embryos.
Constraining the model parameters using experimental data
from aos mutants
We use quantitative experimental data on EGFR-
mediated gene expression in wild type and aos mutant
embryos to constrain the parameters used in the model.
Since the spatial domains of EGFR-target gene expression
are sharp, we model target gene expression in any given
cell using steep functions of the total number of EGFR
Fig. 2. Examples of model functions. (A) The function fs(x), denoting the expression pattern of secreted Spitz. Note that this function is equal to one above the
midline cell and zero everywhere else, because Spitz is secreted by the midline cell only. (B) The function fa(p,x), denoting the pointed-dependent expression
pattern of secreted Argos. Note that this function is equal to one above the cells expressing pointed, and zero everywhere else. (C) The function fr(x), denoting
the expression pattern of EGFR. Note that this function is equal to one above the ventral ectodermal cells and zero over the midline cell. (D) Steady state Spitz
concentration profile. The signal received by cell i is calculated by evaluating the integral under this curve above cell i. The thresholds are calculated based on
the constraints described in the text.
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(and thus of EGFR activity) required for pnt/otd and fasIII
expression by hp and hf, respectively. Thus, ri  hp for
pnt/otd expression in cell i; for fasIII expression we must
have ri  hf.
To determine whether our model can correctly predict
the change in expression patterns of EGFR-target genes in
aos versus wild type embryos, we systematically sampled
the parameters of the model (within the ranges described in
the previous section) and tested their consistency with the
reported aos embryo data. To do this, we solved Eqs. (1)
and (2) for each parameter set in the wild type case,
assuming that Pointed is expressed in two cell rows on
either side of the midline in wild type embryos (Chang et
al., 2001, 2003; Golembo et al., 1996a,b). Next, we used
the modeled Spitz profile to calculate ri for each cell.
Since Pointed is expressed only in cells one and two of
wild type embryos, and not in cell three, cell two must
receive an EGFR signal that exceeds the threshold value
hp, whereas cell three must receive a signal that is below
hp (see Fig. 2D). This rule allowed us to estimate a value
for hp in the wild type ‘‘embryo’’ characterized by a
particular set of values for ks, ka, l, and m. We take hp tobe the average between the signal received by cell two and
the signal received by cell three: hp = (r2 + r3)/2 (see Fig.
2D). Similarly, we take hf as hf = (r5 + r6)/2. Once
computed, the hp and hf values can be used to score
whether or not a particular parameter set (ks, ka, l, m) is
consistent with the experimentally observed expansion of
EGFR-target gene expression domains in the aos embryo.
We scored a parameter set as ‘‘successful’’ if the model
predicted both expansion of the otd domain to 4–6 cell
rows, and expansion of the FasIII domain to 7 cell rows in
the aos mutant (see Figs. 3A, B).
From our calculations, we find that the model based
on sequestration of activating ligand by Argos can
successfully fit the literature data on cell fate expansions
in the aos mutant. Any length scale for Spitz (ks)
between 1 and 10 can predict the correct patterning,
although for ks < 2 the proportion of parameter space for
which this is true is significantly reduced (see Fig. 3C).
Contrary to the earlier argument that Argos is always a
long-ranged diffusible inhibitor of EGFR signaling in
Drosophila, based on clonal analysis experiments in the
eye (Freeman et al., 1992), we find that the Argos length
scale, ka, does not need to be larger than the length scale
Table 1
Model parameters
Parameter Description
Ds Effective diffusivity of Spitz
Da Effective diffusivity of Argos
ks Effective degradation of Spitz
ka Effective degradation of Argos
gs Rhomboid-derived generation of Spitz
ga Pointed-derived generation of Argos
kbind Binding rate constant between Argos and Spitz
L Cell diameter
kec Endocytosis rate of EGFR dimers
RT Threshold # of EGFR dimers for pnt expression
Parameter Grouping Value Description
ks
ﬃﬃﬃﬃﬃﬃﬃﬃ
Ds=ks
p
L
0–10 Length scale of Spitz
ka
ﬃﬃﬃﬃﬃﬃﬃﬃ
Da=ka
p
L
0–10 Length scale of Argos
l kbindga
kska
101–101 Removal rate of Spitz due to
ligand sequestration
m kbindgs
kska
102–102 Removal rate of Argos due to
ligand sequestration
hp kecRT
gsL
– Threshold signaling required
for pnt expression
The first ten parameters are physical constants describing the properties of
the system. The last five are dimensionless groups that arise from scaling
the equations. Each dimensionless group compares two important physical
properties of the system.
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EGFR-target gene expression patterns in aos embryos;
in fact, ka is not constrained at all (see Fig. 3D). Thus, in
light of the recent biochemical demonstration that Argos
inhibits EGFR signaling by sequestering diffusible ligand
rather than blocking non-diffusible receptor, our model
suggests a quite different interpretation for the range of
Argos effects in the ventral ectoderm. Although the length
scale of Argos may differ in distinct developmental
contexts, in ventral ectoderm patterning Argos may in
fact be a short-ranged molecule that remotely inhibits
EGFR by preventing diffusible Spitz from reaching its
intended destination.
Robustness of the EGFR-mediated patterning to altered
gene dosages in wild type embryos
Having established that our model can successfully
account for cell fate expansions in aos embryos, we next
assessed the robustness of the generated fits. This tests
both the quality of the fits and the robustness of the
underlying patterning mechanism. The Spitz gradient, and
hence the gradient of EGFR activation, can in principle be
altered by variations in the level of Spitz secretion from
the midline cell. In addition, the level of EGF receptors inthe ventral ectoderm may affect the morphogen gradient—
even in the ligand limited regime—by a ‘‘ligand trapping’’
mechanism (Casanova and Struhl, 1993) that would
become more prevalent for a given ligand-binding affinity
as the number of receptors increased. By contrast with
these expectations, however, experimental studies show
that expression of EGFR-target genes is unchanged when
the levels of Spitz secretion or receptor concentration are
altered (Golembo et al., 1996a). How much of this
robustness requires tight control of the amount of secreted
morphogen and of the level of the cognate receptor?
Alternatively, how much can be attributed solely to the
structure of the extracellular signaling network and
negative feedback by Argos? We have used our model to
address these questions.
Let as and ar denote the fold changes in the levels of
Spitz secretion and EGFR expression, respectively, relative
to the ‘‘average’’ wild type embryo for which as = ar = 1.
We randomly selected 300 of the parameter sets that were
‘‘successful’’ (as described above) in predicting expansion
of EGFR-target gene expression domains in aos embryos.
For each parameter set, we used the model with wild type
Argos to compute all possible combinations of as and ar
values for which the expression patterns of otd and fasIII
remain identical to wild type. This revealed a series of
robustness, or invariance, regions in the (as, ar)-plane,
inside which the wild type phenotype is maintained. An
example of the invariance region calculated with ks = 3.5,
ka = 4, l = 2.25, m = 1 is shown in Fig. 4A (rightmost gray
region enclosed by blue curve). By measuring the widths of
these invariance regions, we extracted the maximum and
minimum fold-changes in Spitz levels that can be tolerated
by the system (while holding EGFR levels constant at the
wild type level). Similarly, we calculated the system’s
tolerance to changes in EGFR levels alone by measuring
the heights of these regions. This analysis shows that the
network can tolerate significant variations in the doses of
Spitz and EGFR. For example, for the wild type case
shown in Fig. 4A, the network can tolerate nearly a 20%
increase or decrease in rate of Spitz secretion (horizontal
arrows). Even larger perturbations in the EGFR levels are
tolerated; the system retains wild type otd and fasIII
expression patterns even when the EGFR level is increased
to more than double the wild type level and is decreased to
nearly half (vertical arrows). This level of robustness
requires that Spitz sequestration by Argos is very efficient,
i.e., that formation of the Argos/Spitz complex is essen-
tially irreversible, consistent with the very slow off-rates
observed in our surface plasmon resonance studies (Klein
et al., 2004). We find that a model with fast, reversible,
Argos/Spitz binding kinetics fails to produce an expression
pattern that is robust to midline Spitz fluctuations (see
Supplementary Material). Specifically, the wild-type pat-
terns predicted by this ‘‘reversible’’ model could tolerate
changes in EGFR levels or Spitz secretion rates of at most
5%.
Fig. 3. Parameter screen based on aos mutant data. (A, B) In wild type embryos, otd is expressed in two cell rows from the midline (red cells, left-hand panel),
whereas FasIII is expressed in five cell rows (green and red cells, left-hand panel). We use the modeled Spitz profile to calculate ri, the amount of EGFR signal
received by cell i. We then estimate the threshold signal level required for pnt (and hence otd) expression and denote this hp. Similarly, we calculate hf, the
threshold signal level required for FasIII expression. We then use these threshold values to determine the predicted range of otd and FasIII expression in the
aos mutant (right-hand panel). (A) Calculation performed for a ‘‘successful’’ parameter set: ks = 3, ka = 5, l = 3, m = 1. Note that the expansions depicted in
the Argos mutant are consistent with the literature data. (B) Calculation performed for an ‘‘unsuccessful’’ parameter set: ks = 3, ka = 5, l = 5, m = 1. Note that
the expansions depicted in the Argos mutant here are inconsistent with the literature data. (C, D) Distributions of length scales for all parameter sets that are
‘‘successful’’ in fitting the aos mutant data.
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tested, we next asked whether any correlation could be
detected between any of the four dimensionless parameters
shown in Table 1 and the maximum tolerated fold-changes
in levels of EGFR and midline-derived Spitz. As shown in
Figs. 4B, C, the maximal tolerated fold-changes were
strongly correlated with the Spitz length scale, ks. This
behavior is remarkable given that the maximal fold-changes
were computed for a wide range of ks, ka, l, and m. None ofthe other dimensionless parameters showed any significant
correlation with as or ar, including the length scale of Argos
(data not shown).
The computed boundaries for as and ar can be used to
quantify the robustness of the modeled system. The results
shown in Fig. 4B illustrate that the system can tolerate
midline fluctuations of up to 20% based solely on regulation
at the level of Argos and the extracellular patterning
network. Also shown in Fig. 4B is a significant decrease
Fig. 4. Sensitivity of the patterning system to the levels of various components. (A) To determine the robustness of the system, we calculated the fold-changes
in EGFR level (ar) and Spitz secretion rate (as) that the system could tolerate while maintaining a wild-type expression pattern of both sets of marker genes.
These constraints define a region in the (as, ar)-plane that is depicted here for ks = 3, ka = 4, l = 2.25, m = 1 (rightmost gray region enclosed by solid blue
curve). The dashed red curve denotes the corresponding region in the simplified model formulated with a localized, nondiffusible, Argos. The vertical and
horizontal arrows indicate the maximal perturbations to ar or as alone, respectively. The gray region enclosed by green curve shown to the left depicts the
region in this plane where aos mutant embryos will display the wild-type pattern of marker gene expression. (B, C) The maximal tolerated perturbations to the
fold-changes in Spitz secretion rate (depicted as horizontal arrows in (A)) and the EGFR expression level (depicted as vertical arrows in (A)), for all randomly
chosen parameter sets (blue circles), are plotted against the Spitz length scale. The solid red curves denote the corresponding maximal perturbations in the
simplified model with localized Argos. (B) Maximal perturbations to fold-changes in the Spitz secretion rate. (C) Maximal perturbations to fold-changes in the
EGFR level. (D, E) Analysis of the role of the negative feedback loop. The area of the region of Argos mutant rescue and the area of the corresponding wild
type invariance region are compared. (D) Distribution of ratios of these areas found for 300 randomly generated parameter sets. Note that all ratios are
significantly less than 1. (E) Plot of the ratio of these areas versus the Spitz length scale for the 300 randomly generated parameter sets (blue circles). The solid
red curve denotes the same calculation performed with the simplified model with localized Argos. (F) The maximal tolerated perturbations to the fold-changes
in Argos uptake rate for all randomly chosen parameter sets (blue circles), plotted against the Spitz length scale. The solid red curves denote the corresponding
maximal perturbations in the model with localized Argos.
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Spitz dose (as) as ks increases. In contrast to the decreasing
robustness with respect to changes in the Spitz dose as ks
increases, we find that robustness to changes in EGFR
levels (ar) reaches a clear maximum when ks = 3 or 4 celldiameters (Fig. 4C), withstanding up to a 2 1/2 times
increase and a 50% decrease. Again, this robustness is
attributed solely to Argos action and to the inherent
topology of the extracellular signaling module, and does
not take into account other forms of regulation (so
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robustness plot shown in Fig. 4C, we propose that the length
scale of secreted Spitz, which is a function of its diffusion
rate and rate of EGFR-mediated removal, must be 3–4 cells
for maximum robustness; this is consistent with the length
scale estimated from experiments in the eye imaginal disc
(Freeman, 1994).
Robustness of the EGFR/Spitz/Argos network with
respect to changes in the Spitz dose has been demonstrated
previously in experimental studies. Increases in the dose of
midline-derived Spitz do not affect the otd expression
pattern (Golembo et al., 1996b). In addition, embryos
heterozygous for a Spitz null mutation have a normal FasIII
pattern (Golembo et al., 1999). Experiments in mutants with
either reduced or elevated receptor levels have also shown
no phenotypic effect on the spacing of the Keilin’s organs
precursors (Raz and Shilo, 1993). We have experimentally
determined that this robustness can be traced to pattern
formation in the VE. Indeed, the pattern of otd expression in
the ventral ectoderm of stage 11 embryos from mutants with
increased and decreased levels of EGFR was found to be
indistinguishable from that in the wild type (see the EGFR
gene dosage experiments described in Supplementary
Material).
Contribution of Argos to robustness of EGFR-target gene
expression patterns
The negative feedback provided by Argos is not
required in order to achieve the observed wild type pattern
of VE cell fates, which can readily be realized in an open-
loop system without Argos, if the levels of Spitz secretion
and/or EGFR expression are chosen appropriately. Instead,
it has been suggested that one function of negative
feedback signaling through Argos is to contribute to the
observed robustness of VE patterning to perturbations in
the EGFR/Spitz module, which is well described by our
model (Golembo et al., 1996a). To test this hypothesis, we
performed a mathematically controlled comparison (Alves
and Savageau, 2000) between models of the wild type
embryo and an Argos null mutant that was tuned to
generate a wild type cell fate pattern. This analysis
compares the robustness of the same steady state realized
in two different patterning systems, the open-loop (Argos
null) and the closed-loop (wild type).
We quantified changes in the sensitivity of the steady
state gene expression pattern that result solely from
removing the negative feedback loop through Argos by
setting the negative feedback strength, l (see Table 1 and
Supplementary Material), to zero while holding constant as
many other constraints as possible (including the length
scale of Spitz and the two signaling thresholds). Removing
the negative feedback loop in this way has drastic effects on
the steady state pattern, making it impossible to simply
compare the same steady state in both the wild type and
Argos mutant cases. To overcome this difficulty we insteadlooked for the region in the (as, ar)-plane in which the Argos
mutant model predicts ‘‘rescue’’ of the wild type phenotype
(Fig. 4A). We emphasize that, by construction, the wild type
and mutant systems for each (wild type, mutant) pair
evaluated in this manner have identical values for the
thresholds of low- and high-threshold EGFR-target genes.
We found this region of Argos mutant rescue to be
located to the left (lower values of as) of the corresponding
invariance region for the wild type. This is natural,
because rescue of an Argos mutant to wild type should
involve lower levels of Spitz secretion to counteract the
loss of the inhibitor. Next, to score the difference in
sensitivities of the two systems, we computed the ratio of
the area of the Argos mutant rescue region to the area of
the invariance region for the corresponding wild type
system. If the negative feedback loop (which we have
removed) is instrumental in conferring robustness to the
signaling module, the ratio of these areas should be
significantly less than one, as is clearly the case in Fig.
4A. Repeating these calculations for a large range of
parameters, we plotted the distribution of the ratio of these
areas (Fig. 4D) for the randomly generated parameter sets
defined as successful in Fig. 3. The area of the robustness
region in the wild type embryo was always significantly
greater than that of the Argos mutant rescue region. As in
other measures of robustness, the ratio of these areas
correlates well with the length scale of Spitz (Fig. 4E),
with a trend towards increased robustness with decreasing
Spitz length scale. Thus, our computational analysis argues
that Argos contributes significantly to the robustness of the
EGFR/Spitz/Argos signaling system, which can be tested
explicitly in future experiments.
The histogram in Fig. 4D is constructed from all sets of
parameters that pass the screen based on the Argos mutant
data. We have also performed a more detailed analysis of the
sensitivity of the ratio of robustness regions in the wild type
and mutant models to the length scales of Argos and Spitz
(results not shown). Specifically, we have found that the
contribution of the negative feedback to robustness of the
system is anticorrelated with the length scale of Spitz (and
with the dynamic range in the model). By restricting this
analysis to systems with a given dynamic range (that is
tightly correlated with the length scale of Spitz, see Fig. S3
in the Supplementary material), we have found that the
length scale of Argos essentially does not affect the
contribution of the negative feedback to robustness of the
EGFR-target gene expression patterns in the wild type
system. Thus, our conclusion about the contribution of
Argos to robustness of the wild-type patterns does not
depend on the particular value of the Argos length scale.
Argos can achieve its effects on patterning and robustness
by acting at a very short range
As described above, the computational analysis of our
model showed that it can predict both the changes in EGFR
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of the system to varying Spitz and EGFR levels, regardless
of the value employed for the Argos length scale (ka).
Since ka can assume any value without altering our ability
to model these behaviors, it can be zero. In this extreme
case, Argos is modeled as a localized, nondiffusible
inhibitor that sequesters Spitz and prevents its delivery to
distant EGF receptors (Fig. 5A). In the context of VE
patterning, a model of this sort is sufficient to describe the
long-ranged inhibitory action of Argos. As shown in the
Supplementary Material, in this regime, the number of free
parameters in the model can be reduced from four to only
two: the length scale of Spitz, ks, and the effective removal
rate of Spitz by Argos, l. The governing Eqs. (1)–(2)
reduce to:
k2s sxx þ fs xð Þ  s fr xð Þ þ lfa p; xð Þð Þ ¼ 0 ð3Þ
From this equation and the definition of the signaling
thresholds (described above), we can compute the region of
parameter space (ks,l) that correctly predicts changes in
EGFR target gene expression domains in aos embryos.
This region is plotted in Fig. 5B. We find that this
simplified model provides a remarkably accurate approx-
imation of the results generated by our full model. In
particular, the variations in the Spitz and EGFR levels that
are tolerated without changes in the otd and FasIII domains
in this ka = 0 model agree very well with the results of the
full, four-parameter model (see dashed red curve in Fig. 4A
and solid red curves in Figs. 4B, C, E for representative
examples).
In the model with short-ranged Argos (ka = 0), high
levels of EGFR signaling close to the point of Spitz
secretion induce the production of a nondiffusible
inhibitor that acts as a localized ligand-sink. In this case,
inhibition of EGFR signaling by Argos in the VE may be
classified as ‘‘self-enhanced ligand degradation’’. This
general mechanism was recently shown to be robust with
respect to changes in the dose of secreted signal (Eldar etFig. 5. Simplified model with immobile, localized, Argos. (A) Typical Spitz profil
the Spitz profile in the region occupied by Argos. (B) Region of parameter spaceal., 2003). Indeed, essentially every pair of parameters
consistent with the observed cell fate expansions in aos
embryos is robust in the sense that that it predicts a wild
type model that can tolerate significant variations in the
levels of EGFR and locally produced Spitz. Thus, a
mechanism involving remote inhibition of EGFR by
short-ranged Argos can fit the data from Argos null
embryos and provides the basis for explaining the
observed robustness with respect to changes in the level
of locally produced signal and its ubiquitously expressed
receptor.
Sensitivity of the model to cell surface binding (and uptake)
of Argos
We have assumed in our model that Argos binding to
the cell surface represents the primary mode of Argos
removal/degradation from the ventral ectoderm. To ensure
that this assumption does not impact our conclusions, it is
important to determine how dependent are the predictions
of the model on the parameters used to describe this
uptake. We therefore tested the sensitivity of the wild type
steady state pattern to variations in the level of cell surface
Argos binding sites, and thus the Argos removal rate. Let
ah denote the fold change in the level of cell surface Argos
binding sites, relative to the ‘‘average’’ wild-type embryo
for which ah = 1. For the parameter sets identified as
‘‘successful’’ in predicting otd and FasIII expression
patterns in aos embryos, we computed the upper and
lower limits of ah for which the wild type expression
patterns of otd and FasIII remain unchanged. We find that
the network can tolerate more than a 20% decrease in
Argos binding to the cell surface or an increase of at least
50%. This behavior is largely independent of particular
values of the four model parameters (see Fig. 4F). We
therefore conclude that our choice of parameters to
describe this characteristic of Argos does not affect the
qualitative conclusions of our modeling analysis.e depicting the mode of action of localized Argos. Note the rapid decline in
consistent with the aos data.
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We have formulated a computational model for EGFR/
Argos/Spitz interactions based on our recent biochemical
demonstration that Argos interacts directly with Spitz, thus
sequestering the ligand and preventing it from interacting
with (and activating) Drosophila EGFR (Klein et al., 2004).
We have used our model to analyze the patterning capabilities
of this ligand-sequestration mechanism in EGFR-mediated
cell fate determination in the ventral ectoderm. Our model
can be directly correlated with the experimentally observed
patterns of EGFR-target gene expression. We have reduced
the number of free model parameters and developed a
protocol for checking the consistency of any given parameter
set with the published experimental data. Using this protocol,
we find that the ligand sequestration mechanism for Argos
action can successfully describe the experimentally observed
cell fate expansions in aos embryos. The model also
predicts that the EGFR/Spitz/Argos patterning network can
tolerate significant variations in the dose of Spitz and the
level of EGFR expression—and is therefore robust—
provided that the interaction between Argos and Spitz is
significantly stronger than Spitz binding to EGFR, and is
essentially irreversible. This predicted robustness has been
tested and verified experimentally both in our own experi-
ments (see Supplementary Material), and in previously
published studies (Golembo et al., 1996b, 1999; Raz and
Shilo, 1993). In addition, the requirement that Argos/Spitz
binding is essentially irreversible is supported by the very
slow dissociation of the complex seen in our surface plasmon
resonance studies (Klein et al., 2004).
The robustness of the EGFR/Spitz/Argos network to
variations in the Spitz dose indicates that precise patterns of
EGFR-target gene expression in the ventral ectoderm do not
require fine-tuning of Spitz production from the midline.
Through our studies in both the wild type and Argos mutant
networks, we find that this robustness is provided by
negative feedback signaling through Argos. On average,
our analysis indicates that the Argos mutant network is twice
as sensitive (i.e., half as robust) as the wild type embryo to
perturbations in both the Spitz dose and the receptor
expression level.
Another important outcome of our analysis, summarized
in Fig. 3C, is that Argos does not need to be long-ranged in
order for the ligand sequestration mechanism to be
consistent with available experimental data in VE pattern-
ing. We propose that, at least in the embryonic ventral
ectoderm, Argos can remotely inhibit EGFR by acting only
at very short range to sequester locally produced Spitz. This
hypothesis is strongly supported by our demonstration that a
reduced model, with non-diffusing Argos, quantitatively
captures the behavior of the full mechanism over a wide
range of parameter sets. The ultimate test of this prediction
requires experimental visualization of Argos and Spitz
gradients in the VE, and possibly efforts to manipulate
Argos range experimentally.Our model can be extended in a number of ways, and
suggests several additional lines of experiments. First of all,
the current formulation neglects Vein, a neuregulin-like
EGFR ligand that is also induced by Spitz and is expressed
in the same pattern as Argos (Chang et al., 2001; Golembo
et al., 1999; Schnepp et al., 1996). Vein has been shown to
play a role that is partially redundant with Spitz in VE
patterning and appears to be required for maintaining the
wild type domains of lateral EGFR-target gene expression
when Spitz levels are compromised (Golembo et al., 1999;
Schnepp et al., 1996; Skeath, 1998). Quantitative analysis of
these effects in EGFR-mediated patterning requires future
biochemical analysis of EGFR/Vein/Argos interactions,
which are ongoing in our laboratories. A second important
point is that our computational analysis of EGFR-mediated
patterning has focused only on the final steady state pattern
achieved in stage 11. The pathway to generation of this
pattern is complex. The Spitz gradient in the naı¨ve ventral
ectoderm during stages 8–9 is established rapidly, and
Argos is not initially present to modulate Spitz distribution.
Thus, it could be argued that this developmental stage is
analogous to an aos mutant (since Argos expression has
not yet been induced). Indeed, in stages 9–10 that follow,
the domains of EGFR target gene expression are expanded
compared with the stage 11 domains that we consider here
(Gabay et al., 1996; Golembo et al., 1999). While our model
agrees qualitatively with these observations and arguments
(see Supplementary Material), future work should focus on
the transcriptional network downstream of EGFR in these
early stages, and how it is controlled. Specifically, the
network of ETS transcription factors that include Pointed,
Yan, and the auxiliary protein Mae has overlapping feed-
back loops that might contribute to the spatiotemporal
regulation of EGFR activation in the ventral ectoderm
(Vivekanand et al., 2004).
The computational analysis of EGFR inhibition by Argos
presented here sheds light on the functional capabilities of
control of receptor tyrosine kinases by secreted inhibitors.
Our model shows that, by acting as a ligand-induced
‘‘ligand sink’’ produced close to the Spitz source (where
Spitz levels are highest), Argos can act locally (at very short
range) to restrict further Spitz signaling and/or to modulate
the dose of Spitz delivered to distant cells. However, our
model does not rule out the possibility that Argos can act at
longer range, since neither robustness of the system nor the
ability of our model to explain the available experimental
data require that the Argos length scale is small. This raises
the possibility that Argos might act over different ranges in
distinct developmental contexts. For example, studies of the
role of Argos in regulating cell fate decision in the
Drosophila eye argue that it acts over several cell diameters
(Freeman et al., 1992). The action of Argos as a ligand sink
rather than a direct antagonist of the EGF receptor appears
to lend this potential versatility to its function during
development, and the studies presented here suggest future
experiments and computational analyses to explore the
G.T. Reeves et al. / Developmental Biology 284 (2005) 523–535534modes of EGFR regulation by Argos and other related
ligand sinks in more detail.Materials and methods
Fly strains
The following strains were used: Kr-Gal4 is a balanced
double insertion on the third chromosome, directing
expression in the Kruppel domain (segments T2-A4),
UAS-EGFR-GFP and topIK35/cyo a severe allele of the
top gene (Clifford and Schupbach, 1994). All strains were
kindly provided by T. Schu¨pbach.
In situ hybridization of whole-mount embryos
Otd cDNA plasmid was provided by T. Schupbach, and
digoxigenin-labeled antisense RNA probe was prepared
with Roche reagents. Embryos of topIK35/cyo or from a
cross between Kr-Gal4 and UAS-EGFR-GFP strains were
collected for 2 h and aged for 5 h at 25-C (about stage 11),
then hybridized with otd antisense RNA probe, as described
(Gavis and Lehmann, 1992).Acknowledgments
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